# Pilot Study for Cyproheptadine in Hospitalized Patient for COVID-19

> **NCT04876573** · PHASE2 · UNKNOWN · sponsor: **Ciusss de L'Est de l'Île de Montréal** · enrollment: 60 (estimated)

## Conditions studied

- Viral Pneumonia
- COVID-19 Pneumonia
- Serotonin Syndrome
- Platelet Dysfunction

## Interventions

- **DRUG:** Cyproheptadine Hydrochloride 4 MG

## Key facts

- **NCT ID:** NCT04876573
- **Lead sponsor:** Ciusss de L'Est de l'Île de Montréal
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-06-01
- **Primary completion:** 2021-12-31
- **Final completion:** 2022-01-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2021-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04876573

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04876573, "Pilot Study for Cyproheptadine in Hospitalized Patient for COVID-19". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04876573. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*